Nanoparticles, promising carriers in drug targeting: A review

Current Drug Therapy

Volumn 6, Issue 2, 2011, Pages 87-96

  Ram, Yaduvanshi M ^a   Yadav, Hemant K S ^a   Singh, Mangla N ^a   Shivakumar, Hosakote G ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Drug targeting; Immunopathogenesis; Nanoparticles; Polymerization

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ANTIGEN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GANCICLOVIR; GLYCYRRHIZIC ACID; IMMUNOMODULATING AGENT; INSULIN; LOW DENSITY LIPOPROTEIN; MACROGOL; METHOTREXATE; MURAMYL DIPEPTIDE ANALYLCHOLESTEROL; MURAMYL DIPEPTIDE DERIVATIVE; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; POLY(METHYL METHACRYLATE); POLYACRYLAMIDE; POLYLACTIC ACID; POLYMER; PROTAMINE SULFATE; PYRROLIDINE DITHIOCARBAMATE; UNCLASSIFIED DRUG; VACCINE; WATER OIL CREAM;

ARTICLE; CANCER RESISTANCE; CHEMICAL MODIFICATION; CYTOMEGALOVIRUS INFECTION; DIFFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; GELATION; HUMAN; IMMUNE RESPONSE; LIVER; MAGNETISM; MICROEMULSION; MISCIBILITY; MULTIDRUG RESISTANCE; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; STEREOSPECIFICITY; SURFACE PROPERTY;

EID: 79959919646     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488511795304958     Document Type: Article

References (120)

1. Mansoor MA. Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv 2006; 3(2): 205-216.
2. Sajjia HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol 2009; 6: 43-51.
3. Shirzad A, Wilson HR, Raimar L. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev 2008; 60: 863-875.
4. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected campothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 1999; 59: 299-307.
5. Maia SC, Mehnert W, Shafer KM. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm 2000; 165: 165-167.
6. Oyewumi MO, Mumper RJ. Gadolinium-loaded nanoparticles engineered from microemulsion templates. Drug Dev Ind Pharm 2002; 28: 317-328.
7. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
8. Coester CJ, Langer K, von Briessen H, Kreuter J. Gelatin nanoparticles by two step desolvation/ a new preparation method, surface modifications and cell uptake. J Microencapsul 2000; 17: 187-193.
9. Jenning V, Gysler A, Schafer KM, Gohla SH. VitaminA loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to upper skin. Eur J Pharm Biopharm 2000; 49: 211-218.
10. Stella B, Arpicco S, Peracchia MT, et al. Design of folic acidconjugated nanoparticles for drug targeting. J Pharm Sci 2000; 89: 1452-1464.
11. Allen TM, Brandeis E, Hansen CB, Kao GY, Zaplipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Acta Biochim Biophys 1995; 1237: 99-108.
12. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-284.
13. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 11(Suppl 2): 81-91.
14. Kaul G, Amiji M. Long-circulating poly(ethylene glycol)-modified gelatine nanoparticles for intracellular delivery. Pharm Res 2002; 19(7): 1061-1067.
15. Cascante M, Centelles JJ, Veech RL, Lee WN, Boros LG. Role of thiamin (vitamin B-1) and transketolase in tumor cell proliferation. Nutr Cancer 2000; 36(2): 150-154.
16. Park JW, Benz CC, Martin FJ. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 2004; 31(6): 196-205.
17. Edith M. Encyclopedia of Controlled Drug Delivery. 1st ed. John Wiley & Sons Inc. New York 1999.
18. Joshi A. Microparticulates for opthalmic drug delivery. J Ocul Pharmacol 1994; 10: 29-45.
19. Allemann E, Gurny R, Doelker E. Drug loaded nanoparticles -preparation methods and in vivo studies. Eur J Pharm Biopharm 1993; 39: 173-191.
20. Lovell PA, El Aasser MS (Eds). Emulsion Polymerization and Emulsion Polymers. Wiley: New York 1997.
21. James S. Encyclopedia of Pharmaceutical Technology. 3rd ed. Informa Healthcare Inc: New York USA 2007.
22. Fessi H, Devissaguet JP, Puisieux F. Procedé de preparation de systemes colloi{dotless}daux dispersibles d'une substance sous forme de nanoparticules. French Patent 2,608,988, 1986.
23. Marty JJ, Oppenheim RC, Speiser P. Nanoparticles: a new colloidal drug delivery systems. Pharm Acta Helv 1978; 53: 17-23.
24. Weber C, Coester C, Kreuter J, Langer K. Dessolvation process and surface characterization of protein nanoparticles. Int J Pharm 2000; 194: 94-102.
25. Vauthier C, Couvreur P. In: Handbook of Pharmaceutical Controlled Release Technology; Wise, Trantolo, Cichon, Inyang, Stottmeister, Ed. Marcel Dekker Inc. New York 2000; 21: pp. 413-429.
26. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 1995; 17: 31-48.
27. Illum L, Davis SS. The organ uptake of intravenously administered colloidal particles can be altered using non-ionic surfactant (poloxamer 338). FEBS Letters 1984; 167: 79-82.
28. Gref R, Minamitake Y, Peracchia MT, et al. Poly(ethyleneglycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm Biotechnol 1997; 10: 167-198.
29. DeMiguel I, Ioualalen K, Bonnefous M, et al. Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules. Biochim Biophys Acta 1995; 1237: 49-58.
30. Peracchia MT, Desmaele D, Couvreur P, D'Angelo J. Synthesis of a novel poly(PEG-cyanoacrylate-co-alkylcyanoacrylate) amphiphilic copolymer for the development of ''stealth'' PEG-coated nanoparticles. Macromolecules 1997; 30: 846-851.
31. Peracchia MT, Desmaele D, Vauthier C, et al. In: Targeting of Drugs: Strategies for Stealth Therapeutic Systems; Gregoriadis B, McCormack B, Ed. Plenum Press: New York 1998; pp. 225-239.
32. Peracchia MT, Vauthier C, Popa M, Puisieux F, Couvreur P. Investigation of the formation of sterically stabilized poly (ethyleneglycol/isobutylcyanoacrylate) nanoparticles by chemical grafting of poly(ethylene glycol) during polymerization of isobutylcyanoacrylate. STP Pharma Sciences 1997; 7: 513-520.
33. Passirani C, Ferrarini L, Barratt G, Devissaguet JP, Labarre D. Preparation and characterization of nanoparticles bearing heparin or dextran covalently-linked to poly(methylmethacrylate). J Biomater Sci Polym Ed 1999; 10: 47-62.
34. Stella B, Arpicco S, Peracchia MT, et al. Characterization of folic acid-nanoparticles conjugates for tumoral targeting. Proceedings of the 27th International Symposium on Controlled Release of Bioactive Materials of the Controlled Release Society, Inc.; 2000 July 9-13; Paris, France. Abstract # 6307.
35. Kreuter J. Colloidal Drug Delivery Systems. 1st ed Dekker: New York 1994.
36. Davis SS, Illum L, McVie JG, Tomlinson E, Eds. Microspheres and Drug Therapy. 1st Ed. Elsevier: Amsterdam 1984.
37. Akasaka Y, Ueda H, Takayama K, Machida Y, Nagai T. Preparation and evaluation of bovine serum albumin nanospheres coated with monoclonal antibodies. Drug Des Delivery 1988; 3: 85-97.
38. Illum L, Jones PD, Baldwin RW, Davis SS. Tissue distribution of poly(hexyl-2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts. J Pharmacol Exp Ther 1984; 230: 733-736.
39. Couvreur P, Vauthier C. In: De Boer AG, Ed., Drug Absorption Enhancement, Concepts, Possibilities, Limitations and Trends. Harwood Academic Publishers: Switzerland 1994, pp. 457-486.
40. Leroux JC, Doelker E, Gurny R. In: S. Benita, 2 Ed. illus, Microencapsulation Methods and Industrial Applications. Dekker: New York 1996.
41. Birrenbach G, Speiser PP. Polymerized micelles and their use as adjuvants in immunology. J Pharm Sci 1976; 65: 1763-1766.
42. Michel C, Defontaine L, Aprahamian M, et al. Insulin nanocapsules: variations in the biological response depending on the administration site along the digestive tract. In: Whateley TL, ed., Microencapsulation of Drugs. Harwood Academic Publishers: Chur, Switzerland 1992, pp. 233-242.
43. Florence AT. The oral absorption of micro and nanoparticulates neither exceptional nor unusual. Pharm Res 1997; 14: 259-266.
44. O'Hagan DT, Palin KJ, Davis SS. Poly(butyl-2-cyanoacrylate) particles as adjuvants for oral immunization. Vaccine 1989; 7: 213-216.
45. Pappo J, Ermak TH. Uptake and transmission of fluorescent latex particles by rabbit Peyer's patch epithelium: a quantitative model for M cell uptake. Exp Immunol 1989; 76: 144-148.
46. Jelinkova M. Targeting of human and mouse t-lymphocytes by monoclonal antibody-hpma copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J Control Release 1998; 52: 253-270.
47. Negishi M, Irie A, Nagata N, Ichikawa A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta 1991; 1066: 77-82.
48. Ishida S, Sakiya Y, Ichikawa T, Taira Z. Uptake of glycyrrhizin by isolated rat hepatocytes. Biol Pharm Bull 1993; 16: 293-297.
49. Lin AH, Liu YM, Huang Y, et al. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharm 2008; 359: 247-253.
50. Gao Y, Gu WW, Chen LL, Xu ZH, Li YP. A multifunctional nano device as on-viral vector for gene delivery: In vitro Characteristics and transfection. J Control Release 2007; 118: 381-388.
51. Kovár M, Mrkvan T, Strohalm J, et al. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J Control Release 2003; 92: 315-330.
52. Vyas SP, Singh A, Sihorkar V. Ligand-receptor-mediated drug delivery: an emerging paradigm in cellular drug targeting. Crit Rev Ther Drug Carrier Syst 2001; 18: 1-76.
53. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26: 442-449.
54. Li XB, Schluesener HJ, Xu SQ. Molecular addresses of tumors: selection by in vivo phage display. Arch Immunol Ther Exp (Warsz) 2006; 54:177-181.
55. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res 2000; 60: 2300-2303.
56. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central nervous system. J Biol Chem 1987; 262: 14352-60.
57. Lundberg B, Risovic V, Ramaswamy M, Wasan K. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release 2003; 86: 93-100.
58. Firestone RA, Pisano JM, Falck JR, et al. Selective delivery of cytotoxic compounds to cells by the LDL pathway. J Med Chem 1984; 27: 1037-1043.
59. Dubowchik GM, Firestone RA. Improved cytotoxicity of antitumor compounds deliverable by the LDL pathway. Bioconjug Chem 1995; 6: 427-439.
60. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 2007; 328: 86-94.
61. Brzoska M, Langer K, Coester C, Loitsch S, Wagner TOF, Mallinckrodt C. Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases. Biochem Biophys Res Commun 2004; 318: 562-570.
62. Langer K, Coester C, Weber C, von Briesen H, Kreuter J. Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid. Eur J Pharm Biopharm 2000; 49: 303-307.
63. Coester C, Kreuter J, von Briesen H, Langer K. Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA). Int J Pharm 2000; 196: 147-149.
64. Truong LVL, Walsh SM, Schweibert E, et al. Gene transfer by DNA gelatin nanospheres. Arch Biochem Biophys 1998; 361: 47-56.
65. Lisa BP, James OB. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 2004; 56: 1649-1659.
66. Szakacs G, Paterson JK, Ludwig JA, Genthe CB, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-234.
67. Chun L, Sidney W. Polymer drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008; 60: 886-898.
68. Cornelus FVN. Polymeric micelles to deliver photosensitizers for photodynamic therapy. Adv Drug Deliv Rev 2004; 56: 9-16.
69. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 2007; 24:1029-1046.
70. Oh JK, Drumright R, Siegwart DJ, Matyjaszewski K. The development of microgels/nanogels for drug delivery applications. Prog Polym Sci 2008; 33: 448-477.
71. Kawaguchi H. Functional polymer microspheres. Prog Polym Sci 2000; 25: 1171-1210.
72. Alivisatos P. The use of nanocrystals in biological detection. Nat Biotechnol 2004; 22(1): 47-52.
73. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006; 5(8): 1909-1917.
74. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006; 7(8): 657-667.
75. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296(5577): 2404-2407.
76. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52: 3396-3401.
77. Franklin WA, Waintrub M, Edwards D, et al. New anti-lung cancer antibody cluster 12 reacts with human folate receptors present on adenocarcinoma. Int J Cancer 1994; 8: 89-95.
78. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposomeentrapped doxorubicin in vitro. Biochim Biophys Acta 1995; 1233: 134-144.
79. Lee RJ, Huang L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem 1996; 271: 8481-8487.
80. Oyewumi MO, Mumper RJ. Influence of formulation parameters on gadolinium entrapment and tumor cell uptake using folatecoated nanoparticles. Int J Pharm 2003; 25: 85-97.
81. Zhang LK, Hou SX, Mao SJ, Wei DP, Song XR, Lu Y. Uptake of folate-conjugated albumin nanoparticles to the SKOV3 cells. Int J Pharm 2004; 287: 155-162.
82. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51: 5329-5338.
83. Fan L, Li F, Zhang HT, et al. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 2010; 31: 5634-5642.
84. Niendorf A, Nagele H, Gerding D, Meyer PU, Gebhardt A. Increased LDL receptor mRNA expression in colon cancer is correlated with a rise in plasma cholesterol levels after curative surgery. Int J Cancer 1995; 61: 461-464.
85. Chen Y, Hughes FM. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int J Cancer 2001; 91: 41-45.
86. Nakagawa T, Ueyama Y, Nozaki S, et al. Marked hypocholesterolemia in a case with adrenal adenoma-enhanced catabolism of low density lipoprotein (LDL) via the LDL receptors of tumor cells. J Clin Endocrinol Metab 1995; 80: 92-6.
87. Stranzl A, Schmidt H, Winkler R, Kostner GM. Low-density lipoprotein receptor mRNA in human breast cancer cells: influence by PKC modulators. Breast Cancer Res Treat 1997; 42: 195-205.
88. Gal D, McDonald PC, Porter JC, Simpson ER. Cholesterol metabolism in cancer cells in monolayer culture. III. Low-density lipoprotein metabolism. Int J Cancer 1981; 28: 315-9.
89. Vitols S, Peterson C, Larsson O, Holm P, Aberg B. Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo. Cancer Res 1992: 52: 6244-7.
90. Tatidis L, Masquelier M, Vitols S. Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines. Biochem Pharmacol 2002; 63: 2169-80.
91. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme a reductase gene expression in normal and leukemic cells. Blood 1994; 84: 2689-98.
92. Vitols S, Gharton G, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984; 83: 1186-93.
93. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978; 6: 1099-114.
94. Rudling MJ, Angelin B, Peterson CO, Collins VP. Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement. Cancer Res 1990; 50: 483-7.
95. Firestone RA. Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. Bioconjug Chem 1994; 5: 105-13.
96. Rensen PCN, De Vrueh RLA, Kuiper J, Bijsterbosch MK, Biessen EAL, Berkel TJCV. Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 2001; 47: 251-76.
97. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11: 265-83.
98. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. nnu Rev Pharmacol Toxicol 1999; 39: 361-98.
99. Tapiero H, Mishal Z, Wioland M, Silber A, Fourcade A, Zwingelstein G. Changes in biophysical parameters and in phospholipid composition associated with resistance to doxorubicin. Anticancer Res 1986; 6: 649-52.
100. Kellen JA. The reversal of multidrug resistance in cancer (review). Anticancer Res 1993; 13: 959-61.
101. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2002; 54: 631-51.
102. Cuvier C, Roblot TL, Millot JM, et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol 1992; 44: 509-17.
103. de Verdiere AC, Dubernet C, Nemati F, Poupon MF, Puisieux F, Couvreur P. Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemother Pharmacol 1994; 33: 504-8.
104. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem Soc Trans 2007; 35: 56-60.
105. Chavany C, Saison-Behmoares T, LeDoan T, Puisieux F, Couvreur P, Hélène C. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 1994; 11: 1370-8.
106. Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P. Nanocapsules: a new type of lysosomotropic carrier. Fed Eur Biochem Soc Lett 1977; 84: 323-6.
107. Bennis S, Chapey C, Couvreur P, Robert J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer 1994; 1: 89-93.
108. de Verdiere AC, Dubernet C, Nemati F, et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 1997; 76: 198-205.
109. Grislain L, Couvreur P, Lenaerts V, Roland M, Deprez DD, Speiser P. Pharmacokinetics and distribution of a biodegradable drugcarrier. Int J Pharm 1993; 15: 335-45.
110. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
111. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-83.
112. Park JG, Lee SK, Hong IG, et al. MDR1 gene expression: its effect on drug resistance to doxorubicin in human hepatocellular carcinoma cell lines. J Natl Cancer Inst 1994; 86: 700-05.
113. Itsubo M, Ishikawa T, Toda G, Tanaka M. Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 1994; 73: 298-303.
114. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol 2000; 113: 355-63.
115. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12: 569-75.
116. Barraud L, Merle P, Soma E, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol 2005; 42: 736-43.
117. Merodio M, Espuelas MS, Mirshahi M, Arnedo A, Irache JM. Efficacy of ganciclovir-loaded nanoparticles in human cytomegalovirus (HCMV)-infected cells. J Drug Target 2002; 10(3): 231-8.
118. Courveur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 1991; 8(9): 1079-86.
119. Portney NG, Ozkan M. Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 2006; 384(3): 620-30.
120. Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol Sci 2008; 101(1): 4-21.